HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ORMP
Oramed Pharmaceuticals Inc.
There isn't enough reported data to score ORMP yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ORMP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Unavailable |
ORMP's profitability is currently strong. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ORMP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.2x | $4.03 | — |
| Cheap | 1.5x | $5.25 | +30% |
| Fair | 5.7x | $19.40 | +381% |
| Expensive | 85x | $290 | +7101% |
Historical ranges are pointers, not guarantees.
ORMP's PE is 1.2x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ORMP Forward outlook
There aren't enough analyst estimates for ORMP to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ORMP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.43 | +246% |
| Q2 2026 | $4.13 | +$4.75 |
| Q1 2026 | $2.60 | +$3.31 |
| Q4 2025 | $1.50 | +$1.98 |
| Q3 2025 | $0.99 | +$1.03 |
| Q2 2025 | -$0.62 | -272% |
| Q1 2025 | -$0.71 | -745% |
| Q4 2024 | -$0.48 | -443% |
ORMP has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ORMP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $674K | 0% |
| Q1 2023 | $666K | 0% |
| Q4 2022 | $681K | -25% |
| Q3 2022 | $682K | -0.1% |
| Q2 2022 | $674K | -1% |
| Q1 2022 | $666K | +0.2% |
| Q4 2021 | $904K | +34% |
| Q4 2021 | $674K | 0% |
ORMP's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -225% | N/A |
| Q2 2023 | -562% | +1132 points |
| Q1 2023 | -782% | +908 points |
| Q4 2022 | -1430% | -67 points |
| Q3 2022 | -1201% | -4.9 points |
| Q2 2022 | -1694% | -609 points |
| Q1 2022 | -1689% | -791 points |
| Q4 2021 | -1364% | -632 points |
ORMP's operating margin was −225% last quarter, up 976 points from the same quarter a year ago, near the top of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ORMP on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORMP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $422K | +$2M |
| Q2 2026 | -$202K | +$3.3M |
| Q1 2026 | -$2.9M | +$602K |
| Q4 2025 | -$468K | +$1.5M |
| Q3 2025 | -$1.6M | +$5.5M |
| Q2 2025 | -$3.5M | -270% |
| Q1 2025 | -$3.5M | -$2M |
| Q4 2024 | -$1.9M | -$501K |
ORMP has burned cash in almost every quarter: −$3M over the past year, against −$11M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ORMP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ORMP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +514K shares |
| 1 year | +0.6% | +241K shares |
| 3 years | +6.4% | +2.6M shares |
| 5 years | +17% | +6.3M shares |
| Available history | +141% | +25.2M shares |
ORMP has 43M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $4M |
| Q3 2025 | $361,000 |
| Q4 2024 | $1.2M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ORMP Net Leverage
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ORMP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 8.9 | Oversold |
ORMP's weekly RSI is 47 (neutral) and its Stochastic is 9 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ORMP PE vs Healthcare Sector
| Metric | ORMP | Sector median | Relative |
|---|---|---|---|
| PE | 1.2x | 26x | 95% below |
| PE % | 10 | 29 | 19 pts below |
ORMP is trading at 1.2x earnings, a 95% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ORMP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.22 | 4.5% below |
| 20 week MA | $4.38 | 8% below |
| 50 week MA | $3.89 | 3.6% above |
| 100 week MA | $3.08 | 31% above |
| 200 week MA | $2.83 | 42% above |
ORMP has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ORMP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.18 | $4.54 | -12% |
| 2021 | $4.54 | $15.5 | +242% |
| 2022 | $15.5 | $11.0 | -29% |
| 2023 | $11.0 | $2.31 | -79% |
| 2024 | $2.31 | $2.37 | +2.6% |
| 2025 | $2.37 | $2.95 | +24% |
| 2026 YTD | $2.95 | $4.03 | +37% |
ORMP has the edge over HIMS on returns for 2026, with the stronger performance.